119th Congress · introduced in the House · Feb 18, 2025
Enhancing Domestic Drug Manufacturing Competitiveness Act
Official title from Congress.gov
Latest action (Feb 18, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 18, 2025)
Enhancing Domestic Drug Manufacturing Competitiveness Act
This bill requires the Government Accountability Office (GAO) to study and report to Congress on key regulatory barriers to pharmaceutical manufacturing in the United States.
Specifically, GAO must identify and assess, including by engaging stakeholders, barriers that impede expansion or siting of pharmaceutical manufacturing facilities in the United States or make the United States less competitive than other countries as a location for such facilities. GAO must consider (1) whether environmental or other regulations significantly delay and increase the cost of expanding or siting pharmaceutical manufacturing facilities in the United States; (2) the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency; and (3) specific actions for regulators to address the identified barriers.
Finally, the report must include recommendations for streamlining regulatory barriers and facilitating technological solutions to foster U.S. pharmaceutical manufacturing.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Administrative law and regulatory procedures · Congressional oversight · Environmental regulatory procedures · Government studies and investigations · Manufacturing · Prescription drugs
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
1 citation.
SENTINEL API GROUP, INC. · lobbying firm or registrant: EXECUTIVE STRATEGIES, LTD. CO.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Manufacturing
$20,000
Paid to lobbying firm
…mestic API production; implementation of Executive Order(s) or federal policy aimed at boosting U.S.-based pharmaceutical manufacturing; relevant provisions of H.R. 1405 (Enhancing Domestic Drug Manufacturing Act), S. 257 (Promoting Resilient Supply Chains Act of 2025), the RAPID Reserve Act, and other pending bills and actions…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing